Peapod Lane Capital LLC Takes Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Peapod Lane Capital LLC acquired a new stake in Kodiak Sciences Inc. (NASDAQ:KOD) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 166,843 shares of the company’s stock, valued at approximately $1,660,000. Kodiak Sciences accounts for 1.6% of Peapod Lane Capital LLC’s holdings, making the stock its 26th biggest holding. Peapod Lane Capital LLC owned approximately 0.32% of Kodiak Sciences at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. LJI Wealth Management LLC grew its position in Kodiak Sciences by 21.3% in the 3rd quarter. LJI Wealth Management LLC now owns 17,100 shares of the company’s stock valued at $45,000 after acquiring an additional 3,000 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Kodiak Sciences by 61.4% in the fourth quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock valued at $206,000 after purchasing an additional 7,871 shares during the period. Geode Capital Management LLC grew its holdings in shares of Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after purchasing an additional 12,783 shares in the last quarter. State Street Corp increased its stake in Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after buying an additional 14,711 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Kodiak Sciences during the 2nd quarter worth approximately $36,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 9th. HC Wainwright reiterated a “neutral” rating and issued a $3.00 target price on shares of Kodiak Sciences in a report on Friday, November 15th. Finally, Barclays boosted their target price on Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Friday, November 15th.

Kodiak Sciences Stock Down 6.6 %

NASDAQ KOD opened at $4.99 on Thursday. Kodiak Sciences Inc. has a 52 week low of $2.18 and a 52 week high of $11.60. The firm has a 50 day moving average of $8.08 and a two-hundred day moving average of $5.13. The stock has a market capitalization of $262.57 million, a PE ratio of -1.37 and a beta of 2.06.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.